Paxlovid is the first anti-Covid-19 antiviral to obtain an early access authorization. It is a treatment primarily for risk populations (elderly, immunocompromised etc.).
Le Monde with AFP
The High Authority of Health (HAS) authorized, Friday 21 January, the use of the Paxlovid antiviral Pfizer laboratory as curative treatment against COVID 19. Paxlovid is the first anti-Covid antiviral to obtain an authorization early access.
Following the opinion of the National Medicine Safety Agency (ANSM), the HAS “authorizes early access to the Paxlovid (Nirmatrelvir / Ritonavir) treatment of the Pfizer laboratory for adults with CVIV-19 requiring No oxygen therapy and high risk of evolution towards a serious shape of the disease “. It is therefore a treatment primarily for risky populations (elderly, immunocompromised etc.).
on prescription by general practitioners
This pill is administered orally at the rate of three tablets per day for five days. It is recommended to take it as soon as possible after the positive diagnosis of COVID-19 and maximum within five days of the appearance of symptoms. Effective against the Omicron Variant, this treatment reduces by about 85% the risk of being hospitalized or deceiving from CVIV-19, according to clinical studies.
HAS notes, however, that antiviral is contraindicated in people with severe liver failure or severe renal failure. It also points out the significant risk of drug interactions when taking paxlovid for patients taking another treatment.
“We booked 500,000 doses in 2022 and the first deliveries – a few thousand doses – are expected in a week,” said Thursday the entourage of the Minister of Health Olivier Véran at the France-Presse agency ( AFP). Its deployment will be done in particular via a prescription by general practitioners, in all pharmacies.